Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11239-021-02561-w http://scihub22266oqcxt.onion/10.1007/s11239-021-02561-w 34498156!8425464!34498156     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Thromb+Thrombolysis 2022 ; 53 (2): 346-351 Nephropedia Template TP {{tp|p=34498156|t=2022. Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone |pdf=|usr=}}{{34498156}} gab.com Text Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone JO: J Thromb Thrombolysis http://www.kidney.de/pget.php?&tw=1&pmid=34498156 #FOAvip Direct oral anticoagulants (DOACs) are not recommended in COVID-19 patients receiving dexamethasone because of potential drug-drug and drug-disease interactions affecting anticoagulant concentration and activity. To evaluate short- and long-term pharmacokinetic interactions, serial through and peak DOAC plasma levels were prospectively measured during and after dexamethasone therapy, as well as during the acute phase and after recovery from COVID-19 in hospitalized, non-critically ill patients undergoing treatment with DOACs. Thirty-three (18 males, mean age 79 years) consecutive patients received DOACs (17 apixaban, 12 rivaroxaban, 4 edoxaban) for atrial fibrillation (n = 22), venous thromboembolism (n = 10), and acute myocardial infarction (n = 1). Twenty-six patients also received dexamethasone at a dose of 6 mg once daily for a median of 14 days. Trough DOAC levels on dexamethasone were within and below expected reference ranges respectively in 87.5 and 8.3% of patients, with no statistically significant differences at 48-72 h and 14-21 days after dexamethasone discontinuation. Peak DOAC levels on dexamethasone were within expected reference ranges in 58.3% of patients, and below ranges in 33.3%, of whom over two thirds had low values also off dexamethasone. No significant differences in DOAC levels were found during hospitalization and after resolution of COVID-19. Overall, 28 patients were discharged alive, and none experienced thrombotic or bleeding events. In this study, dexamethasone administration or acute COVID-19 seemed not to affect DOAC levels in hospitalized, non-critically ill COVID-19 patients. Twit Text FOAVip Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone ????J Thromb Thrombolysis http://www.kidney.de/pget.php?&tw=1&pmid=34498156 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34498156 #FOAvip English Wikipedia <ref>{{Cite pmid|34498156}}</ref> Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone #MMPMID34498156 Potere N; Candeloro M; Porreca E; Marinari S; Federici C; Auciello R; Di Nisio M J Thromb Thrombolysis 2022[Feb]; 53 (2): 346-351 PMID34498156show ga Direct oral anticoagulants (DOACs) are not recommended in COVID-19 patients receiving dexamethasone because of potential drug-drug and drug-disease interactions affecting anticoagulant concentration and activity. To evaluate short- and long-term pharmacokinetic interactions, serial through and peak DOAC plasma levels were prospectively measured during and after dexamethasone therapy, as well as during the acute phase and after recovery from COVID-19 in hospitalized, non-critically ill patients undergoing treatment with DOACs. Thirty-three (18 males, mean age 79 years) consecutive patients received DOACs (17 apixaban, 12 rivaroxaban, 4 edoxaban) for atrial fibrillation (n = 22), venous thromboembolism (n = 10), and acute myocardial infarction (n = 1). Twenty-six patients also received dexamethasone at a dose of 6 mg once daily for a median of 14 days. Trough DOAC levels on dexamethasone were within and below expected reference ranges respectively in 87.5 and 8.3% of patients, with no statistically significant differences at 48-72 h and 14-21 days after dexamethasone discontinuation. Peak DOAC levels on dexamethasone were within expected reference ranges in 58.3% of patients, and below ranges in 33.3%, of whom over two thirds had low values also off dexamethasone. No significant differences in DOAC levels were found during hospitalization and after resolution of COVID-19. Overall, 28 patients were discharged alive, and none experienced thrombotic or bleeding events. In this study, dexamethasone administration or acute COVID-19 seemed not to affect DOAC levels in hospitalized, non-critically ill COVID-19 patients. |*Anticoagulants/therapeutic use[MESH] |*Atrial Fibrillation/drug therapy[MESH] |*COVID-19 Drug Treatment[MESH] |*Dexamethasone/therapeutic use[MESH] |Administration, Oral[MESH] |Aged[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Pyridones/therapeutic use[MESH] |Rivaroxaban/therapeutic use[MESH]Direct oral anticoagulant plasma levels in hospitalized COVID-19 patie(epmc).pdf DeepDyve Pubget Overpricing